Joincare(600380)2024-04-25 13:04Financial Performance - The company's operating revenue for Q1 2024 was CNY 4,339,814,452.16, a decrease of 4.81% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 439,798,106.55, down 4.96% year-on-year[4] - The revenue from chemical preparations was CNY 2,141 million, a decline of 4.86% year-on-year, with hormone products showing a growth of 39.89% to CNY 807 million[5] - The company reported a significant increase in revenue from diagnostic reagents and equipment, which rose by 60.26% to CNY 236 million[5] - The company’s basic earnings per share for Q1 2024 were CNY 0.2357, a decrease of 1.96% year-on-year[4] - The company’s weighted average return on equity decreased by 0.34 percentage points to 3.15%[4] - Total operating revenue for Q1 2024 was approximately ¥4.34 billion, a decrease of 4.8% compared to ¥4.56 billion in Q1 2023[18] - Net profit for Q1 2024 reached approximately ¥925.1 million, an increase of 5.3% from ¥878.5 million in Q1 2023[18] - Operating profit for Q1 2024 was approximately ¥1.09 billion, up from ¥1.05 billion in Q1 2023, reflecting a growth of 4.0%[18] - Total comprehensive income for Q1 2024 was approximately ¥902.6 million, compared to ¥794.8 million in Q1 2023, indicating an increase of 13.6%[19] - Basic earnings per share for Q1 2024 were ¥0.2357, slightly down from ¥0.2404 in Q1 2023[19] - The total operating costs for Q1 2024 were approximately ¥3.30 billion, down from ¥3.56 billion in Q1 2023, reflecting a decrease of 7.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 291.91% to CNY 972,276,972.65, primarily due to reduced procurement and expense expenditures[7] - Cash flow from operating activities for Q1 2024 was approximately ¥972.3 million, significantly higher than ¥248.1 million in Q1 2023[20] - Current assets totaled RMB 23,443,751,168.49, down from RMB 23,874,630,390.40 at the end of 2023, primarily due to a decrease in cash and cash equivalents[16] - The company's cash and cash equivalents decreased to RMB 15,118,198,045.39 from RMB 15,691,888,314.83, reflecting a decline of approximately 3.65%[16] - Accounts receivable increased to RMB 2,641,495,146.49 from RMB 2,692,941,866.24, indicating a slight rise in receivables[16] - Total assets at the end of Q1 2024 were CNY 36,462,147,240.89, reflecting a slight increase of 0.29% from the end of the previous year[4] - The non-current assets increased to RMB 13,018,396,072.40 from RMB 12,483,495,868.42, reflecting a growth of approximately 4.29%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,332[11] - The largest shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., holds 895,653,653 shares, accounting for 47.98% of the total shares[11] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 87,780,030 shares, representing 4.70%[11] - The company reported a total of 9,370,400 shares under the third phase of the long-term partner shareholding plan[12] - The shareholding structure indicates no related party relationships among the top shareholders[12] - The top 10 shareholders collectively hold a significant portion of the shares, with the largest shareholder alone holding nearly half[11] - The company has not reported any significant changes in the shareholding structure due to margin trading activities[13] - The total shares held by the China Agricultural Bank's CSI 500 ETF amounted to 10,353,414, representing 0.55% of the total shares[13] Liabilities and Equity - Total liabilities decreased to RMB 12,925,489,486.86 from RMB 13,718,595,768.18, showing a reduction of approximately 5.78%[17] - The company's equity attributable to shareholders rose to RMB 14,234,869,509.55 from RMB 13,755,901,924.06, an increase of about 3.48%[17] - Short-term borrowings decreased significantly to RMB 1,360,009,625.00 from RMB 2,076,159,347.22, a reduction of approximately 34.5%[17] - The company reported a decrease in current liabilities, totaling RMB 9,865,306,342.16 compared to RMB 9,860,687,845.52 at the end of 2023[17] - The company’s retained earnings increased to RMB 9,878,656,063.35 from RMB 9,441,857,956.80, indicating a growth of about 4.64%[17] Audit and Reporting - The report does not indicate any significant operational issues during the reporting period[15] - There were no audit opinion types applicable for the quarterly financial statements[15] - Health元药业集团将于2024年首次执行新会计准则[22] - 2024年第一季度财务报表未涉及调整[22] - 健康元药业集团于2024年4月25日发布财报[22] - 2024年第一季度报告包含12页内容[22] - 报告未提及具体业绩数据和用户数据[22] - 未来展望和业绩指引未在报告中详细说明[22] - 新产品和新技术研发的相关信息未披露[22] - 市场扩张和并购策略未在报告中提及[22] - 其他新策略的具体内容未被列出[22] - 报告未提供具体的财务指标和百分比[22]